Rare Germline Pathogenic Mutations of DNA Repair Genes Are Most Strongly Associated with Grade Group 5 Prostate Cancer

Lichtenstein, 2000, Environmental and heritable factors in the causation of cancer—analyses of cohorts of twins, N Engl J Med, 343, 78, 10.1056/NEJM200007133430201 Mucci, 2016, Familial risk and heritability of cancer among twins in Nordic countries, JAMA, 315, 68, 10.1001/jama.2015.17703 Schumacher, 2018, Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci, Nat Genet, 50, 928, 10.1038/s41588-018-0142-8 Kote-Jarai, 2011, BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients, Br J Cancer, 105, 1230, 10.1038/bjc.2011.383 Pritchard, 2016, Inherited DNA-repair gene mutations in men with metastatic prostate cancer, N Engl J Med, 375, 443, 10.1056/NEJMoa1603144 Leongamornlert, 2019, Germline DNA repair gene mutations in young-onset prostate cancer cases in the UK: evidence for a more extensive genetic panel, Eur Urol, 76, 329, 10.1016/j.eururo.2019.01.050 Na, 2017, Germline mutations in ATM and BRCA1/2 distinguish risk for lethal and indolent prostate cancer and are associated with early age at death, Eur Urol, 71, 740, 10.1016/j.eururo.2016.11.033 Castro, 2013, Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer, J Clin Oncol, 31, 1748, 10.1200/JCO.2012.43.1882 Carter, 2019, Germline mutations in ATM and BRCA1/2 are associated with grade reclassification in men on active surveillance for prostate cancer, Eur Urol, 75, 743, 10.1016/j.eururo.2018.09.021 Mateo, 2015, DNA-repair defects and olaparib in metastatic prostate cancer, N Engl J Med, 373, 1697, 10.1056/NEJMoa1506859 Mateo, 2018, Clinical outcome of prostate cancer patients with germline DNA repair mutations: retrospective analysis from an international study, Eur Urol, 73, 687, 10.1016/j.eururo.2018.01.010 Marshall, 2019, Differential response to olaparib treatment among men with metastatic castration-resistant prostate cancer harboring BRCA1 or BRCA2 versus ATM mutations, Eur Urol, 76, 452, 10.1016/j.eururo.2019.02.002 National Comprehensive Cancer Network, 2018 Giri, 2018, Role of genetic testing for inherited prostate cancer risk: Philadelphia Prostate Cancer Consensus Conference 2017, J Clin Oncol, 36, 414, 10.1200/JCO.2017.74.1173 Mu, 2016, Sanger confirmation is required to achieve optimal sensitivity and specificity in next-generation sequencing panel testing, J Mol Diagn, 18, 923, 10.1016/j.jmoldx.2016.07.006 Richards, 2015, Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology, Genet Med, 17, 405, 10.1038/gim.2015.30 Nicolosi, 2019, Prevalence of germline variants in prostate cancer and implications for current genetic testing guidelines, JAMA Oncol, 5, 523, 10.1001/jamaoncol.2018.6760 Ewing, 2012, Germline mutations in HOXB13 and prostate-cancer risk, N Engl J Med, 366, 141, 10.1056/NEJMoa1110000 Xu, 2013, HOXB13 is a susceptibility gene for prostate cancer: results from the International Consortium for Prostate Cancer Genetics (ICPCG), Hum Genet, 132, 5, 10.1007/s00439-012-1229-4 Cremers, 2015, The role of the prostate cancer gene 3 urine test in addition to serum prostate-specific antigen level in prostate cancer screening among breast cancer, early-onset gene mutation carriers, Urol Oncol, 33, 10.1016/j.urolonc.2015.01.018 Oliva L, Lozano R, Llacer C, et al. Risk prediction tools available for germline BRCA1/2 mutations underperform in prostate cancer patients. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2019.06.019. Page, 2019, Interim results from the IMPACT study: evidence for prostate-specific antigen screening in BRCA2 mutation carriers, Eur Urol, 76, 831, 10.1016/j.eururo.2019.08.019 Mateo, 2019, PARP inhibitors for advanced prostate cancer: validating predictive biomarkers, Eur Urol, 76, 459, 10.1016/j.eururo.2019.03.029 Antonarakis, 2018, Germline DNA-repair gene mutations and outcomes in men with metastatic castration-resistant prostate cancer receiving first-line abiraterone and enzalutamide, Eur Urol, 74, 218, 10.1016/j.eururo.2018.01.035 Hussain, 2018, Targeting androgen receptor and DNA repair in metastatic castration-resistant prostate cancer: results from NCI 9012, J Clin Oncol, 36, 991, 10.1200/JCO.2017.75.7310 Antonarakis, 2019, Clinical features and therapeutic outcomes in men with advanced prostate cancer and DNA mismatch repair gene mutations, Eur Urol, 75, 378, 10.1016/j.eururo.2018.10.009 Guedes, 2017, MSH2 loss in primary prostate cancer, Clin Cancer Res, 23, 6863, 10.1158/1078-0432.CCR-17-0955 Invitae, 2019 Wu, 2018, A comprehensive evaluation of CHEK2 germline mutations in men with prostate cancer, Prostate, 78, 607, 10.1002/pros.23505 Lin, 2019, Re: Daniel A. Leongamornlert, Edward J. Saunders, Sarah Wakerell, et al., Germline DNA repair gene mutations in young-onset prostate cancer cases in the UK: evidence for a more extensive genetic panel. Eur Urol 2019;76:329–37, Eur Urol, 76, e128, 10.1016/j.eururo.2019.06.013 Chandrasekar T, Gross L, Gomella LG, Hegarty SE, Leong JY, Giri VN. Prevalence of suspected hereditary cancer syndromes and germline mutations among a diverse cohort of probands reporting a family history of prostate cancer: toward informing cascade testing for men. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2019.06.010